



NDA 19-367/S-015

Baxter Healthcare Corporation  
Route 120 & Wilson Road; RLT-10  
Round Lake, IL 60073

Attention: Marcia Marconi  
Vice President, Regulatory Affairs

Dear Ms. Marconi:

Please refer to your supplemental new drug application dated December 24, 1999, received December 27, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Potassium Chloride in 5% Dextrose and Lactated Ringer's Injection, USP in Plastic container.

We acknowledge receipt of your submission dated January 11, 2002, which constituted a complete response to our November 15, 2001, action letter.

This supplement proposes labeling changes in response to the December 13, 1994, Federal Register Notice entitled, "Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of "Pediatric Use" Subsection in the Labeling."

We have completed the review of this supplemental application, as amended, and it is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted January 11, 2002).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 19367/S-015." Approval of this submission by FDA is not required before the labeling is used.

In addition, all previous revisions as reflected in the most recently approved labeling must be included. To facilitate review of your submission, please provide a highlighted or marked-up copy that shows the changes that are being made.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

NDA 19-367/S-015

Page 2

If a letter communicating important information about these drug products (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to appropriate NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Ms. Lisa Malandro, Regulatory Health Project Manager, at (301) 827-7410.

Sincerely,

*{See appended electronic signature page}*

Bob Rappaport, M.D.  
Acting Director  
Division of Anesthetic, Critical Care, and  
Addiction Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Bob Rappaport  
1/3/03 11:38:08 AM